Skip to content
Menu

ADARx Pharmaceuticals, Inc. ADRX

Full chart Compare
Set alert

Price alert · ADRX

All alert types
12.79 USD -1.37 (-9.68%)

Regular-session close

12.79 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

12.66 Day range 14.86
12.79 52-week range 20.64
YTD
-33.90%
1 year
-33.90%

5D -2.15 (-14.22%)

131415MonTueWedThuFri12.97
Market cap
1.42B
Revenue (ttm)
6.79M
EPS (ttm)
-6.75
Shares out
111.19M
Forward P/E
-8.27
YTD return
-33.90%
1-year return
-33.90%
50-day average
16.79
Volume
708.83K
Avg volume
649.17K
Open
14.03
Previous close
14.16
Day's range
12.66 – 14.86
52-week range
12.79 – 20.64
Analysts
Strong Buy
Price target
33.75 (+163.9%)

Key statistics

200-day average
16.79
Enterprise value
679.95M
Price / sales
208.66
Revenue growth
42.60%
Total cash
901.01M
Total debt
6.46M

Fundamental scorecard

5 of 25 checks passed on ADRX’s reported financials

ValueGrowthProfitabilityHealthDividend

5of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ADRX Revenue — quarterly 2.22M
ADRX Net income — quarterly -28.12M
ADRX EPS — quarterly -1.74

Earnings

ADRX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2026Dec 30, 2026-0.40-1.74-1.34-335.00%
Sep 2, 2026Sep 30, 2026-0.82169-2.27-1.45-176.26%

Upgrades / downgrades

ADRX analyst upgrades and downgrades
DateFirmActionFromTo
Oct 20, 2026TD Coweninit—Buy
Oct 20, 2026JP Morganinit—Overweight
Oct 20, 2026UBSinit—Buy
Oct 20, 2026Morgan Stanleyinit—Overweight

About ADARx Pharmaceuticals, Inc.

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer's disease. The company was incorporated in 2019 and is based in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
adarx.com

News

Your note

Sign in to keep a note on ADRX — it syncs with the Stock Master app.

Insider holders

ADRX insider holders
InsiderRelationLatest transactionDateShares held
CHIMOVITS EREZDirectorPurchaseSep 27, 20260
GEORGE SIMEON J.Director and Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 27, 20260
GORDON CARL LDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 27, 20260
LAV BIOSCIENCES FUND V LPBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securitySep 27, 20260
ORBIMED ADVISORS, L.L.C.Beneficial Owner of more than 10% of a Class of SecurityPurchaseSep 27, 20260
SR ONE CAPITAL MANAGEMENT, LLCBeneficial Owner of more than 10% of a Class of SecurityPurchaseSep 27, 20260

Institution ownership

ADRX institution ownership
Holder% heldSharesValueReported
Orbimed Advisors LLC.21.77%24,205,789308.38MSep 29, 2026
SR One Capital Management, LP8.94%9,936,661126.59MSep 29, 2026
Bain Capital Life Sciences Investors, LLC6.05%6,728,97085.73MSep 29, 2026
TCG Crossover Management, LLC3.70%4,116,45252.44MSep 29, 2026
FMR, LLC3.28%3,646,09046.45MSep 29, 2026
Price (T.Rowe) Associates Inc2.60%2,894,39636.87MSep 29, 2026

Fund ownership

ADRX fund ownership
Holder% heldSharesValueReported
SmallCap World Fund Inc2.92%3,246,80141.36MSep 29, 2026
Fidelity Contrafund0.42%467,7005.96MSep 29, 2026
AB CAP FUND, INC.-AB Small Cap Growth Portfolio0.39%430,7295.49MSep 29, 2026
AB DISCOVERY GROWTH FUND, INC.0.38%427,3165.44MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.36%400,0005.10MSep 29, 2026
Fidelity Securities Fund-Fidelity Blue Chip Growth Fund0.30%328,2004.18MSep 29, 2026